Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies

There is an urgent need for earlier diagnosis of malignancies and more stringent monitoring of relapses after antitumor therapy. In addition, new prognostic markers are needed for risk stratification and design of individualized cancer therapies. New diagnostic and prognostic parameters should overc...

Full description

Saved in:
Bibliographic Details
Main Authors: Sebastian Kobold, Tim Luetkens, Yanran Cao, Carsten Bokemeyer, Djordje Atanackovic
Format: Article
Language:English
Published: Wiley 2010-01-01
Series:Clinical and Developmental Immunology
Online Access:http://dx.doi.org/10.1155/2010/721531
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849434647356768256
author Sebastian Kobold
Tim Luetkens
Yanran Cao
Carsten Bokemeyer
Djordje Atanackovic
author_facet Sebastian Kobold
Tim Luetkens
Yanran Cao
Carsten Bokemeyer
Djordje Atanackovic
author_sort Sebastian Kobold
collection DOAJ
description There is an urgent need for earlier diagnosis of malignancies and more stringent monitoring of relapses after antitumor therapy. In addition, new prognostic markers are needed for risk stratification and design of individualized cancer therapies. New diagnostic and prognostic parameters should overcome the impairments of current standards in a cost-effective manner. Serological approaches measuring spontaneous antibody responses against tumor-associated antigens could be of use as diagnostic and prognostic markers and could also be employed to evaluate response to therapy in cancer patients. Autoantibodies have been suggested to be of frequent and specific occurrence in patients with malignancies and to correlate with clinical parameters. Screening the relevant literature on this topic, we suggest that the analysis of single antibody specificities is unlikely to provide sufficient diagnostic and prognostic accuracy. The combined analysis of autoantibodies targeting different antigens, however, may reach high sensitivity and specificity. In addition, screening cancer patients for autoantibodies might identify subgroups with high relapse risk and a worse prognosis. Larger prospective trials should be initiated to identify sets of tumor-associated autoantibodies suited for the use in diagnostic algorithms for cancer detection and followup.
format Article
id doaj-art-e9c51ce91b7e41d0a40682e6c6f30d11
institution Kabale University
issn 1740-2522
1740-2530
language English
publishDate 2010-01-01
publisher Wiley
record_format Article
series Clinical and Developmental Immunology
spelling doaj-art-e9c51ce91b7e41d0a40682e6c6f30d112025-08-20T03:26:34ZengWileyClinical and Developmental Immunology1740-25221740-25302010-01-01201010.1155/2010/721531721531Prognostic and Diagnostic Value of Spontaneous Tumor-Related AntibodiesSebastian Kobold0Tim Luetkens1Yanran Cao2Carsten Bokemeyer3Djordje Atanackovic4Department of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyDepartment of Oncology, Hematology, Stem Cell Transplantation with the section Pneumology, University Cancer Center Hamburg (Hubertus Wald Tumorzentrum), University Medical Center Hamburg-Eppendorf, 20246 Hamburg, GermanyThere is an urgent need for earlier diagnosis of malignancies and more stringent monitoring of relapses after antitumor therapy. In addition, new prognostic markers are needed for risk stratification and design of individualized cancer therapies. New diagnostic and prognostic parameters should overcome the impairments of current standards in a cost-effective manner. Serological approaches measuring spontaneous antibody responses against tumor-associated antigens could be of use as diagnostic and prognostic markers and could also be employed to evaluate response to therapy in cancer patients. Autoantibodies have been suggested to be of frequent and specific occurrence in patients with malignancies and to correlate with clinical parameters. Screening the relevant literature on this topic, we suggest that the analysis of single antibody specificities is unlikely to provide sufficient diagnostic and prognostic accuracy. The combined analysis of autoantibodies targeting different antigens, however, may reach high sensitivity and specificity. In addition, screening cancer patients for autoantibodies might identify subgroups with high relapse risk and a worse prognosis. Larger prospective trials should be initiated to identify sets of tumor-associated autoantibodies suited for the use in diagnostic algorithms for cancer detection and followup.http://dx.doi.org/10.1155/2010/721531
spellingShingle Sebastian Kobold
Tim Luetkens
Yanran Cao
Carsten Bokemeyer
Djordje Atanackovic
Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies
Clinical and Developmental Immunology
title Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies
title_full Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies
title_fullStr Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies
title_full_unstemmed Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies
title_short Prognostic and Diagnostic Value of Spontaneous Tumor-Related Antibodies
title_sort prognostic and diagnostic value of spontaneous tumor related antibodies
url http://dx.doi.org/10.1155/2010/721531
work_keys_str_mv AT sebastiankobold prognosticanddiagnosticvalueofspontaneoustumorrelatedantibodies
AT timluetkens prognosticanddiagnosticvalueofspontaneoustumorrelatedantibodies
AT yanrancao prognosticanddiagnosticvalueofspontaneoustumorrelatedantibodies
AT carstenbokemeyer prognosticanddiagnosticvalueofspontaneoustumorrelatedantibodies
AT djordjeatanackovic prognosticanddiagnosticvalueofspontaneoustumorrelatedantibodies